Acute Coronary Syndrome
Conditions
Keywords
pharmaceutical care service, clinical pharmacist, Cardiac rehabilitation unit, Acute coronary syndrome, patient education and counselling
Brief summary
This study aims to investigate the role of clinical pharmacist in the development of a pharmaceutical care program for patients with Acute coronary syndrome tailored to their specific learning needs and their cultural context, and to verify the program's effects on physiological factors and recurrent symptoms or cardiac events.
Interventions
BEHAVIORALpharmaceutical care service
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Are diagnosed with Acute coronary syndrome (ischemic heart disease) by their primary cardiologist, treated with medication, percutaneous coronary angioplasty, or coronary artery bypass graft. 2. At 20-79 years of age. 3. Has the ability to perform regular physical activity according to the patients' self-identification and the judgment of their primary cardiologist. 4. Willing to participate in this study. 5. Able to be reached by telephone postdischarge.
Exclusion criteria
1. Patients with cognitive impairment. 2. If they need professional help to take their medication at home. 3. With terminal illness. 4. Inability to communicate. 5. Severe arrhythmia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the level of patient education about disease, drugs and lifestyle modification using coronary artery disease education questionnaire (CADE-Q) | three months | at baseline and after three months |
| Assessment of medications adherence: (Eight-item Morisky adherence questionnaire). | three months | at baseline and after three months |
| Change in the number of solved drug-related problems | three months | assessment of drug-related problems at baseline and solving them during three months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of smoker's dependence on cigarette smoking: (using the Fagerstrom Test for Nicotine Dependence). | three months | at baseline and after three months |
| Assessment of quality of life: (36-items self-care Health survey (SF-36)). | three months | at baseline and after three months |
| Change in heart rate [HR] (Bpm). | three months | at baseline and after three months |
| Change in Lipid profile : total cholesterol (mg/dl), triglycerides(mg/dl), and low density lipoprotein cholesterol(mg/dl), high density lipoprotein (mg/dl) | three months | at baseline and after three months |
| Change in levels of fasting blood glucose (mg/dl) | three months | at baseline and after three months |
| Change in systolic and diastolic blood pressure [BP] (mmHg). | three months | at baseline and after three months |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in sodium (mmol/l). | three months | at baseline and after three months |
| Change in waist circumference (cm). | three months | at baseline and after three months |
| Change in Liver function tests: aspartate aminotransferase enzyme (AST) (u/l), alanine aminotransferase (ALT) (u/l) | three months | at baseline and after three months |
| Change in Kidney function tests : serum urea (mg/dl). | three months | at baseline and after three months |
| Change in anthropometric measurements (body mass index [BMI] (Kg/m^2)) | three months | at baseline and after three months |
| Change in serum creatinine (mg/dl). | three months | at baseline and after three months |
| Change in potassium (mmol/l). | three months | at baseline and after three months |
Countries
Egypt
Outcome results
None listed